Brokerages Set Voyager Therapeutics Inc (VYGR) PT at $26.90

Voyager Therapeutics Inc (NASDAQ:VYGR) has been given a consensus recommendation of “Buy” by the sixteen research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $26.90.

A number of equities research analysts have recently commented on the company. Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 6th. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. BTIG Research started coverage on Voyager Therapeutics in a report on Tuesday, December 19th. They issued a “buy” rating and a $32.00 target price for the company. Piper Jaffray Companies restated an “overweight” rating and issued a $28.00 target price on shares of Voyager Therapeutics in a report on Tuesday, November 28th. Finally, Wedbush restated an “outperform” rating and issued a $26.00 target price (up previously from $22.00) on shares of Voyager Therapeutics in a report on Monday, November 20th.

In other news, insider Bernard Ravina sold 3,630 shares of the stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $16.40, for a total value of $59,532.00. Following the completion of the sale, the insider now owns 7,353 shares in the company, valued at $120,589.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 14,610 shares of company stock valued at $207,158 in the last 90 days. Corporate insiders own 8.00% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Voyager Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after acquiring an additional 13,194 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Voyager Therapeutics by 312.8% during the third quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock worth $7,766,000 after acquiring an additional 285,806 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter worth $5,155,000. DAFNA Capital Management LLC raised its holdings in shares of Voyager Therapeutics by 187.2% during the second quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after acquiring an additional 133,488 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Voyager Therapeutics by 11.8% during the second quarter. State Street Corp now owns 184,526 shares of the company’s stock worth $1,653,000 after acquiring an additional 19,471 shares in the last quarter. Institutional investors and hedge funds own 35.97% of the company’s stock.

Shares of Voyager Therapeutics (VYGR) traded up $0.11 during trading hours on Tuesday, hitting $18.38. The stock had a trading volume of 212,557 shares, compared to its average volume of 390,426. Voyager Therapeutics has a one year low of $8.10 and a one year high of $25.99. The firm has a market cap of $495.33 and a P/E ratio of -6.47.

ILLEGAL ACTIVITY WARNING: This story was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://stocknewstimes.com/2018/01/13/brokerages-set-voyager-therapeutics-inc-vygr-pt-at-26-90.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply